CD274 and non-small cell lung carcinoma: The United States Food and Drug Administration (FDA) has approved immunohistochemistry (IHC) for assessing PD-L1 expression in patients with non-small cell lung cancer (NSCLC), melanoma, bladder cancer, and cervical cancer (5, 6).